About Velsera
Velsera is a Healthcare company based in Boston (United States) founded in 2022. AI-based omic data analysis tool for researchers. Velsera has completed 1 acquisition, including PierianDx. Its chief executive, as recorded, is Gavin Nichols. Velsera offers products and services including Seven Bridges, GRAF, ARIA, Clinical Genomics Workspace, and Knowledgebase. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Informatics. Similar companies include Helix, Benchling and BioAge Labs; 3 of its 3 listed similar companies have raised funding.
Company details
Velsera was founded in 2022 in Boston, United States, within the biotechnology sector. Software is developed by the company to support omic data analysis, including features for annotation, reporting, sample processing, and workflow automation. Assistance is provided for disease diagnosis through these tools, which are utilized by researchers in genomic and related fields. Operations focus on enhancing data handling efficiency in research environments.
- Headquarters Boston, United States
- SectorsHealthcare
- Website velsera.com
- Social LinkedIn X Facebook
- Investments & Acquisitions
Products & Services of Velsera
Velsera offers a comprehensive portfolio of products and services, including Seven Bridges, GRAF, ARIA, Clinical Genomics Workspace, and Knowledgebase.
Platform for bioinformatic analysis and pipeline development in research.
Tool for advanced reference genome analysis and variant detection.
Platform for secure data harmonization and sharing in health tech.
Tool for clinical NGS reporting and decision support in diagnostics.
Database for IVD-grade variant analysis in precision medicine.
People of Velsera
93 people are tracked at Velsera (20 in leadership, 73 in team).
| Name | Role | Group |
|---|---|---|
Gavin Nichols | CEO | Leadership |
Rutika Naik | Senior Director/ Head Knowledgebase Development And Delivery | Leadership |
Rakesh Nagarajan | Chief Medical Officer | Leadership |
Aditya Phatak | Head Of Engineering, Asia | Leadership |
Francine Blumental de Abreu Ph.D., Hcld, Cc (ABB ABB) | Senior Director Of Clinical Services And Medical Director | Leadership |
Zelia Worman | Director Of Researcher Engagement And Education | Leadership |
Eugene Hui | Director Of Product Management | Leadership |
Guy Emslie Fca | Global CFO | Leadership |
Shannon Tayon | Director, Global Controller | Leadership |
Rupali Pathak | Director HR - People Operations India | Leadership |
Nikola Mirkovic | Director Of Product Management | Leadership |
Will Moller | Director Of Product Management | Leadership |
George A. Buchanan | Senior Director, Contract Management | Leadership |
Ct Angela Williams Ms (ASCP) | Director STEM | Leadership |
Liam Scott | Vice President Of Customer Support | Leadership |
Andrea Creppel | Senior Director, Head Of Commercial Enablement (learning And Development) With Velsera | Leadership |
Lou Clarke | Senior Director, Business Partners | Leadership |
Pavan Kalantri | Vice President Of Architecture | Leadership |
Anthony Hennessy | VP Of Finance | Leadership |
Chelsea Cantin | People Operations Business Partner | Leadership |
73 more people are available in the full profile.
Complete people profiles for Velsera
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Velsera
Velsera has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include PierianDx.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Genetic tests for individualized disease diagnosis are provided. | pieriandx.com | Saint Louis, United States | 2014 | Jan 2023 | •••• |
Complete acquisition details for Velsera
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Velsera
2 dated milestones of Velsera across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Velsera is founded.
- Acquisition Acquires PierianDx.
Similar companies to Velsera
Velsera has 3 listed similar companies in our database, 3 of them funded. They include Helix, Benchling and BioAge Labs.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| helix.com | 2015 | San Francisco, United States | $435M | Genomic database for clinical research is provided. | ||
| benchling.com | 2012 | San Francisco, United States | $411.9M | 640 | Cloud-based bioinformatics platform is offered for biotech research. | |
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. |
Detailed similar companies of Velsera
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Velsera
The website of Velsera (velsera.com) receives about 6.7K visits a month.
- Monthly visits6.7K
▲ 55.8% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Velsera (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Velsera
Complete news archive for Velsera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Velsera
Velsera was founded in 2022.
Velsera is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Gavin Nichols is the CEO of Velsera, as recorded in our data.
Velsera was founded in 2022 in Boston, United States, within the biotechnology sector. Software is developed by the company to support omic data analysis, including features for annotation, reporting, sample processing, and workflow automation. Assistance is provided for disease diagnosis through these tools, which are utilized by researchers in genomic and related fields. Operations focus on enhancing data handling efficiency in research environments.
Velsera's top competitors include Helix, Benchling and BioAge Labs.
Velsera offers Seven Bridges, GRAF, ARIA, Clinical Genomics Workspace, and Knowledgebase.
Velsera has made 1 acquisition, including PierianDx.